Alveo Technologies is developing diagnostics for early detection of illness and disease. As is seen with the SARS-Cov-2 pandemic, infectious diseases affect everyone, everywhere. Alveo is addressing this problem by providing rapid, reliable and economical cloud-based diagnostics. To achieve this, Alveo condenses all the current diagnostic methods into a single-step process known as the be.well platform. The steps include sample preparation, nucleic acid amplification and real-time detection in a single isothermal microfluidic channel. Alveo hopes to use this information to track global infectious diseases by having at-home diagnostic results. The company is currently developing the platform for Flu A/B, COVID-19 and RSV.
Claim company profile to post jobs directly on this page and this website.